Clinical trial
Safety and Immunogenicity Study of GSK Biologicals' Influenza Vaccine GSK2340272A in Adults Aged 18 Years and Above
NCT00968526 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Safety and Immunogenicity Study of GSK Biologicals' Influenza Vaccine GSK2340272A in Adults Aged 18 Years and Above
- Lead sponsor
- GlaxoSmithKline
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- September 8, 2009
- Completion date
- September 23, 2010
- Enrollment
- 240 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
influenza